ST101-101 Phase 1-2 Study in Advanced Cancer
Research type
Research Study
Full title
A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
IRAS ID
276534
Contact name
Gina Capiaux
Contact email
Sponsor organisation
Sapience Therapeutics, Inc.
Eudract number
2019-004213-13
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 0 months, 29 days
Research summary
This study is a multicenter study conducted in oncology centers at hospitals in the United Kingdom and the United States. The Sponsor is trying to find the safest and most effective dose of the medicine ST101 for people with tumors that are spreading and cannot be removed by surgery. ST101 is an experimental cancer medication that has been shown to inhibit tumor growth in animal studies. Therefore, the Sponsor will be evaluating the optimal dose of the medication and evaluating the medicine's anti-tumor activity in 4 different cancers. This study will explore the safety and efficacy of ST101 in patients with advanced cancer. A typical patient will receive 6 months of treatment (until progression or study withdrawal) followed by 4 months of follow-up.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
20/NE/0159
Date of REC Opinion
13 Jul 2020
REC opinion
Further Information Favourable Opinion